International Clinical Trial: A prospective, single-arm, multicenter phase II clinical study evaluating the first-line treatment of advanced unresectable pancreatic ductal adenocarcinoma with the combination of Rilafupa, apatinib, and the AG chemotherapy regimen

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129230) titled 'A prospective, single-arm, multicenter phase II clinical study evaluating the first-line treatment of advanced unresectable pancreatic ductal adenocarcinoma with the combination of Rilafupa, apatinib, and the AG chemotherapy regimen' on Aug. 1.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The first hospital of Shanxi Medical University

Condition: Patients with pancreatic ductal adenocarcinoma confirmed by histological or cytological examination and locally advanced or metastatic pancreatic cancer that is unresectable as confirmed by imaging studies

Recruitment Status: Not Recrui...